Blood Test May Predict Future Cognitive Decline in Preclinic

Plasma p-tau217 can help identify amyloid-beta–positive individuals with preclinical Alzheimer's disease who are most likely to deteriorate in the coming years, new research suggests.

Related Keywords

Sweden , Phoenix , Arizona , United States , Wisconsin , Swedish , Eric Reiman , Oskar Hansson , Lund University , Research Implications , Banner Alzheimer Institute , Medscape Medical , Wisconsin Registry , Mini Mental State Examination , Preclinical Alzheimer Cognitive Composite , Medscape Medical News , Banner Alzheimer , Alzheimers Disease , Lzheimer Disease , Plasma , Amyloid Beta , Blood , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medical Technology , Biomarker , Iological Marker , Clinical Research , Clinical Trials , Linical Studies , Dementia , Csf , Disease Modifying Therapy , Mt , Geriatrics Elder Care , Positron Emission Tomography Pet , Pet , Ositron Emission Tomogr ,